ACI
ALXN

AMP Capital Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

AMP Capital Investors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-93,949
Closed -$17.3M – 1204
2021
Q2 		$17.3M Sell
93,949
-2,041
-2% -$350K 0.08% 274
2021
Q1 		$14.7M Sell
95,990
-6,049
-6% -$936K 0.07% 297
2020
Q4 		$15.9M Sell
102,039
-20,072
-16% -$2.58M 0.09% 267
2020
Q3 		$13.7M Sell
122,111
-15,076
-11% -$1.63M 0.08% 266
2020
Q2 		$15.3M Sell
137,187
-16,823
-11% -$1.79M 0.1% 234
2020
Q1 		$13.4M Sell
154,010
-5,663
-4% -$556K 0.1% 218
2019
Q4 		$17.1M Buy
159,673
+43,819
+38% +$4.69M 0.09% 250
2019
Q3 		$11.3M Buy
115,854
+39,904
+53% +$4.5M 0.06% 331
2019
Q2 		$9.58M Sell
75,950
-4,213
-5% -$543K 0.05% 365
2019
Q1 		$10.7M Buy
80,163
+11,719
+17% +$1.46M 0.06% 342
2018
Q4 		$6.65M Sell
68,444
-203
-0.3% -$24K 0.04% 432
2018
Q3 		$9.49M Sell
68,647
-27,446
-29% -$3.44M 0.05% 385
2018
Q2 		$11.9M Buy
96,093
+12,565
+15% +$1.47M 0.07% 329
2018
Q1 		$9.24M Sell
83,528
-13,358
-14% -$1.6M 0.05% 394
2017
Q4 		$11.6M Buy
96,886
+8,525
+10% +$1.04M 0.06% 338
2017
Q3 		$12.4M Buy
88,361
+9,427
+12% +$1.28M 0.07% 302
2017
Q2 		$9.66M Sell
78,934
-4,399
-5% -$512K 0.06% 354
2017
Q1 		$10.2M Sell
83,333
-1,700
-2% -$219K 0.06% 343
2016
Q4 		$10.5M Sell
85,033
-2,219
-3% -$272K 0.06% 333
2016
Q3 		$10.5M Buy
87,252
+580
+0.7% +$74.7K 0.06% 309
2016
Q2 		$9.89M Buy
86,672
+2,430
+3% +$345K 0.07% 305
2016
Q1 		$11.4M Sell
84,242
-33,869
-29% -$4.97M 0.08% 271
2015
Q4 		$22.6M Buy
118,111
+5,627
+5% +$983K 0.15% 148
2015
Q3 		$16.6M Buy
112,484
+5,020
+5% +$916K 0.12% 186
2015
Q2 		$19.1M Buy
107,464
+40,722
+61% +$7.03M 0.12% 200
2015
Q1 		$12M Sell
66,742
-32,640
-33% -$5.91M 0.07% 295
2014
Q4 		$18.4M Buy
99,382
+22,954
+30% +$4.25M 0.11% 221
2014
Q3 		$12.8M Buy
76,428
+3,766
+5% +$618K 0.08% 281
2014
Q2 		$11.5M Buy
72,662
+14,110
+24% +$2.23M 0.07% 316
2014
Q1 		$8.75M Buy
58,552
+14,600
+33% +$2.32M 0.06% 376
2013
Q4 		$5.83M Buy
43,952
+7,218
+20% +$866K 0.04% 469
2013
Q3 		$4.28M Sell
36,734
-41,900
-53% -$4.6M 0.03% 523
2013
Q2 		$7.38M Buy
+78,634
New +$7.58M 0.06% 358

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

AMP Capital Investors's ALXN Position: Q3 2021 in Review

AMP Capital Investors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 93,949 shares — an estimated $17.3M sold.

AMP Capital Investors first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $22.6M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • AMP Capital Investors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • AMP Capital Investors sold 93,949 Alexion Pharmaceuticals shares in Q3 2021, an estimated $17.3M.
  • AMP Capital Investors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • AMP Capital Investors's Alexion Pharmaceuticals position peaked at $22.6M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on AMP Capital Investors's 13F filing for Q3 2021, filed 15 Nov 2021.